{{Rsnum
|rsid=2119067
|Gene=SCN2A
|Chromosome=2
|position=165270773
|Orientation=minus
|GMAF=0.2016
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SCN2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 58.4 | 38.1 | 3.5
| HCB | 61.0 | 30.1 | 8.8
| JPT | 59.3 | 34.5 | 6.2
| YRI | 83.6 | 15.8 | 0.7
| ASW | 80.7 | 19.3 | 0.0
| CHB | 61.0 | 30.1 | 8.8
| CHD | 61.1 | 31.5 | 7.4
| GIH | 60.4 | 34.7 | 5.0
| LWK | 75.5 | 23.6 | 0.9
| MEX | 51.7 | 41.4 | 6.9
| MKK | 92.3 | 7.7 | 0.0
| TSI | 71.6 | 24.5 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2119067
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19118814
|Annotation=This variant is significantly associated with late-onset Alzheimer disease (LOAD) in a GWAS study with 492 LOAD cases and 498 cognitive controls using Illumina's HumanHap550 beadchip.
|Drugs=
|Drug Classes=
|Diseases=Alzheimer Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA162363814
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2119067
|overall_frequency_n=107
|overall_frequency_d=128
|overall_frequency=0.835938
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=92
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}